

FEB 22 2002

PATENT & TRADEMARK OFFICE
U.S. DEPARTMENT OF COMMERCECOPY OF PAPERS
ORIGINALLY FILED

Please type a plus sign (+) inside this box →

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

4

Application Number

09/220,920

Filing Date

December 24, 1998

First Named Inventor

Milbrandt et al.

Group Art Unit

1646

Examiner Name

Joseph F. Murphy, Ph.D.

TECH CENTER 1600/2600

MAR 05 2002

RECEIVED

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declarations(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks It is believed that no fee is required. However, if this is incorrect and a fee is required, you are hereby authorized to charge any deficiencies or credit any overpayments to Deposit Account 20-0823. A duplicate copy of this letter is enclosed.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual Name	Thompson Coburn LLP		
Signature			
Date	2/4/02		


CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:

02/04/02

Typed or printed name	Daniel S. Kasten		
Signature		Date	02/04/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



COPY OF PAPERS
ORIGINALLY FILED

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:

02/04/02

Typed or printed name	Daniel S. Kasten	Date	02/04/02
Signature			

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Milbrandt et al.	Group No.: 1646
Serial No.: 09/220,920	Atty. Docket No.: 56029-7996
Filed: December 24, 1998	
For: Artemin, A Neurotrophic Factor	Examiner: Joseph F. Murphy, Ph.D.

Box Non Fee Amendment
Commissioner of Patents and Trademarks
Washington, DC 20231

RECEIVED
MAR 6 2002
TECH CENT 16 1/2000
21/3
M.Q.J.
3/13/02
(NE)

RESPONSE AND AMENDMENT

In response to the Office Action, paper no. 20, mailed on December 26, 2001, please enter the following amendments and remarks intended to put the above-identified application into form for allowance.

IN THE CLAIMS:

15. (Five times amended) An isolated nucleic acid molecule comprising no more than 10,000 nucleotides, wherein said nucleic acid molecule encodes a naturally occurring artemin amino acid sequence or a fragment thereof that is biologically equivalent to artemin, and wherein said artemin amino acid sequence is at least 88% identical to SEQ ID NO:26, and wherein said artemin amino acid sequence promotes survival of neurons.